Abcam, ab234105, Anti-CD130 (gp130) antibody [EPR21732] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CD130 (gp130) antibody. Carrier free. Suitable for WB, I-ELISA and reacts with Human, Recombinant full length protein - Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR21732,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab234105 is the carrier-free version of
ab217671
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD130 also known as gp130 or the IL-6 signal transducer (IL6ST) is a protein weighing around 130 kDa. This receptor is encoded by the IL6ST gene and widely expressed on the surface of cells across multiple tissues. CD130 functions mechanically as a signal transducing receptor facilitating the assembly of receptor complexes necessary for the initiation of signal transduction. It plays a major role in cytokine receptor signaling particularly interacting with interleukin-6 (IL-6) family cytokines.
Biological function summary
CD130 functions as part of the high-affinity receptor complex for certain cytokines. It partners with other receptors such as CD126 to form a complex that initiates signaling pathways after ligand binding contributing to a range of immune responses. Its role is thorough across many cellular processes including differentiation proliferation and apoptosis. In addition to immune signaling CD130 is involved in several growth factor signaling pathways.
Pathways
CD130 serves a significant role in signal transduction particularly in the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. It works in concert with related proteins like JAK1 and STAT3 to transmit signals from extracellular cytokines to the nucleus influencing gene expression. Additionally CD130 can also be found active in the MAPK/ERK pathway which is important for cellular response to growth signals.
CD130 plays a connection especially to inflammatory conditions and certain cancers. Aberrant signaling involving CD130 has been linked to disorders like rheumatoid arthritis where it contributes to the inflammation process. Additionally it relates to multiple myeloma a cancer where abnormal CD130 interactions with proteins like IL-6 may enhance cell survival and proliferation presenting potential targets for therapeutic intervention.